Biologic medications employed in targeted RA therapies encompass TNF-α inhibitors (such as infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol); rituximab, which targets the B cell–specific CD 20 antigen; abatacept, which inhibits T-cell co-stimulation; and tocilizumab, which blocks the IL-6 receptor [98–102]. Here, TNF is linked to rheumatoid arthritis.